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1. Introduction  
Human Immunodeficiency Virus (HIV) is the causative agent of AIDS (Acquired Immune 
Deficiency Syndrome). Currently, the infection by HIV is considered as one of the major 
problem of public health and social stability. The scale of HIV/AIDS epidemic has exceeded 
all expectations since its identification 30 years ago. Currently, according to the report on 
HIV/AIDS by UNAIDS and World Health Organization (WHO) in 2009, we estimated 
approximately 33 million people are currently living with HIV-1 and about 25 millions have 
already died (Piot, Feachem et al. 2004). HIV infection leads to a decline in the number of T 
helper CD4 cells leading to a progressive dysfunction of the immune system. This 
weakening of the immune system results in the development of opportunistic infections 
leading to death of the patient. Despite prevention policies and anti-retroviral therapies, 
AIDS still remains one of the most serious humanitarian crises that we have never known. 
1.1 HIV taxonomy, structure and genome organization 
Identified in 1983, HIV belongs to lentivirus genus of Retroviridaea (Barre-Sinoussi, Chermann 
et al. 1983). Lentiviruses are host-specific viruses which cause slowly progressive diseases in 
their hosts and are characterized by selective T CD4 depletion (Fauci 1988) associated with a 
severe immunological and neurological disorders. These disorders are amplified by the fact 
that the virus infects the key cells of the immune system. As consequences, immunological 
disorders in HIV infected patients are observed since the asymptomatic stage. Two major 
subtypes of HIV have been identified: HIV-1 and HIV-2 (Clavel, Guetard et al. 1986). The first, 
HIV-1, is world wide, virulent and responsible of HIV infection globally. However, the second, 
HIV-2, is less pathogenic and is largely confined to West Africa. These two types of virus share 
a 40% homology in their sequences. HIV-1 strain is subdivided into three genetically groups: 
M (Major), N (New or non M non O) and O (Outlier) (Clavel, Guetard et al. 1986). The M strain 
is the most spread worldwide, it represents more than 95% of the global virus isolates. The 
variability within the sequence of env gene of HIV-1, allowed it to be subdivided into 10 clades 
A to L (McCutchan 2000). At least 15 additional circulating recombinant forms (CRF) has been 
identified in HIV-1 patients living in different geographic regions of the world (Peeters and 
Sharp 2000). However, the presence of these CRF seems to be more present in Africa, Asia and 
South of America. Despite the high sequence homology between HIV-1 and HIV-2 and the 
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existence of co-infection in vivo with the two viruses, no recombination between HIV-1 and -2 
have been reported. About the question of the origin of HIV-1 and HIV-2 transmission to 
human, it is admitted that it comes respectively from a cross-species of SIVcpz (Simian 
Immunodeficiency Virus which infects chimpanzees) in Central Africa and SIVsm (Simian 
Immunodeficiency Virus which infects sooty mangabey) in West Africa (Hirsch, Olmsted et al. 
1989; Gao, Gorelick et al. 2003). 
HIV-1 is an enveloped virus. The viral particles are produced as immature virions by 
budding from infected cells. After maturation by the viral protease, mature particles adopt 
spherical forms with a diameter of 90-100 nm (figure 1). 
 
 
This spatial representation takes into account and summarizes the results from more than 100 latest 
scientific publications in the fields of virology, X-ray analysis and NMR spectroscopy. The depicted 
spatial configurations of 17 different viral and cellular proteins found in HIV particle are in strict 
accordance with known 3D-structures. This model of HIV virion is put on the cover of the special issue 
of Nature Medicine (September 8, 2010) prepared by the Global HIV Vaccine Enterprise. 
Fig. 1. Model reconstitution of spatial structure of HIV-1. 
Those mature particles have a cone shaped core composed of the p24 viral protein. It was 
estimated that each viral particle contains 1500-2000 Gag and 100-200 Pol molecules. The 
envelope glycoproteins are present as trimers of gp120/gp41 and were estimated to ten 
trimers per particle. The HIV capsid contains the viral genome composed of two identical 
single stranded RNA molecules allowing the establishment of frequent genetic changes by 
recombination. The RNA viral genome is capped at its 5’-end and polyadenylated at its 3’-
end. The viral reverse transcriptase, integrase and nucleoproteins were found associated 
with the viral genome. The HIV genome of approximately 10kb encodes for 16 distinct 
proteins (Sodroski, Rosen et al. 1985). A schematic representation of HIV genome and 
proteins is illustrated in figure 2. As in all retroviruses, those proteins are derived from three 
essential genes gag, pol and env. The first gene gag encodes for Gag precursor p55, which is 
cleaved by viral protease to give capside, matrice and nucleocapside proteins : p24, p17, p7 
and p6. Enzymatic proteins are encoded by pol gene and give three viral enzymes : protease 
p11, transcriptase reverse p65/51 and integrase p32. The env gene encodes for the precursor 
gp160 which is later proteotically cleaved by a cellular protease into the two envelope 
proteins gp120 and gp41. These steps of maturation by the viral or the cellular proteases are 
crucial for the production of infectious viral particles. In addition to these structural and 
enzymatic gene products, HIV genome encodes for two regulatory proteins Tat 
(transcriptional transactivator) and Rev (regulator of virion gene expression) and also for 
four accessory proteins : Vif (viral infectivity factor), Vpr (viral protein r), Vpu (viral protein  
www.intechopen.com
HIV Infection «HIV Tat Protein, a Key Factor 
in Pathogenesis and Immune System Dysregulation: Implication of IL-10» 
 
27 
 
 
Gag (group specific antigen) and Gag-Pol (polymerase) are polyprotein precursors that are processed 
by viral protease. The 9 mature subunits are protease (PR), reverse transcriptase (RT), integrase (IN), 
matrix (MA), capsid (CA), p2, nucleocapside (NC), p1 and p6. Envelope is also cleaved, however by a 
host cellular protease into surface (SU) gp120 and transmembrane gp41 moieties. HIV genome encodes 
also for accessory and regulatory proteins: transcriptional transactivator (Tat), regulator of virion gene 
expression (Said, Dupuy et al.), viral infectivity factor (Vif), viral proteins u (Vpu), viral proteins r (Vpr) 
and negative factor (Nef). Tev contains Tat, Env and Rev sequences and functions like Tat and Rev. 
Fig. 2. HIV genome organization and proteins.  
u) and Nef (negatif factor) (Emerman and Malim 1998). The gene products of rev and tat are 
produced early in the viral cycle and their expression is essential for the viral replication. 
Deletion of one of them leads to an abortive viral cycle. The Tat protein is implicated in the 
initiation and elongation/stabilisation of transcribed viral mRNA. Tat binds to a specific site 
called TAR (Tat responsive region) located in the LTR. Tat is the major protein involved in 
the upregulation of HIV-1 replication. In parallel, the Rev protein interacts with a structure 
called RRE (Rev responsive element) located in the env gene (Emerman and Malim 1998). 
This interaction permits mono and unspliced mRNA to cross the nuclear membrane in order 
to enter in the cytoplasm, where, they will be translated to proteins or encapsidated in the 
nascent viral particles. As Tat and Rev, Nef is also an early produced protein. This protein 
has at least three distinct activities including down regulation of cell surface CD4 and MHC 
class I molecules and enhancement of virion infectivity. It has been reported that this protein 
is essential for proviral DNA synthesis. It is also important for cell-cell transmission of the 
virus. In fact, the Vif protein seems to be involved in the final stages of the nucleoprotein 
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core packaging (Peterlin and Trono 2003). The Vpr protein affects the nuclear localization of 
viral nucleic acids in non dividing cells and induces cell differentiation (Peterlin and Trono 
2003), while the Vpu protein enhances virion release and degrades CD4 in the endoplasmic 
reticulum (Hoglund, Ohagen et al. 1994). Many studies have put forward that Vpr, Vif, Nef 
and perhaps Tat are found associated in the viral particles.  
1.2 HIV-1 tropism and replication cycle 
At least 11 distinct steps can be identified in HIV-1 viral cycle including: viral attachment, 
entry by fusion and uncoating, reverse transcription of the RNA genome by reverse 
transcriptase to double stranded DNA (dsDNA), nuclear translocation of the pre-integration 
complex, integration of the proviral dsDNA, transcription of the proviral genome after 
cellular activation, splicing and nuclear transport of mono and unspliced RNA, translation 
of the viral RNA, assembly and packaging of the genomic RNA, budding to give immature 
viral particles and maturation to give infectious viral particles. Since the infection are 
mediated through the bodily fluids, HIV infects specially CD4 positive cells and essentially 
T-CD4 helper cells, monocyte/macrophage and dendritic cells (DC) (Dalgleish, Beverley et 
al. 1984). The virus enters cells by fusion and endocytosis (Chambers, Pringle et al. 1990; 
Bernstein, Tucker et al. 1995). Productive infection of target cells is initiated by the binding 
of the external envelope glycoprotein gp120 to CD4 receptor on the cell surface membrane 
(Bour, Geleziunas et al. 1995). At the surface of the virus the trimer of gp120 is associated 
with three molecules of the transmembrane gp41 by non-covalent interactions. CD4-gp120 
interaction is mediated by conserved domains of gp120 and the first domain of CD4 
receptor. Different reports have shown that gp120 interacts with CD4 with high affinity with 
dissociation constant of nanomolar level (Fenouillet, Clerget-Raslain et al. 1989). It is 
interesting to note that the conserved domains of gp120 appear to be few or non-
immunogenic in HIV-1 infected patients. Generation antibodies against the conserved 
domains of gp120 are of great interest. In fact, despite the great variability observed in HIV-
1 sequence, all viruses recognize the same receptor CD4. Thus, the production of such 
antibodies will probably exhibit a large spectrum of HIV neutralization by blocking gp120-
CD4 interaction with all HIV-1 subtypes despite their variability. A great number of studies 
are working to design potential vaccine candidates based on these conserved domains of 
HIV-1 envelope glycoproteins. Entry of HIV requires also an interaction of gp120 with a 
coreceptor: CCR5 (R5 tropic virus) and/or CXCR4 (X4 tropic virus) (Maddon, Dalgleish et 
al. 1986; Kozak, Platt et al. 1997; Platt, Wehrly et al. 1998). At the time of primo-infection, 
HIV recognizes and infects principally cells that express CCR5 proteins 
(monocytes/macrophages) (Dragic, Litwin et al. 1996). With time the virus switch from R5 
to X4 tropic to infects T cells (Grivel and Margolis 1999; Shankarappa, Margolick et al. 1999). 
This tropic evolution correlates with late stage of HIV infection : AIDS stage. Thus, 
interaction of gp120 to CD4 receptor and coreceptors induces HIV entry by allowing viral 
and host cell membranes fusion. This mechanism continues to be largely investigated at a 
molecular level, by different groups. We will briefly summarize here the key steps.  
Subsequently to gp120-CD4 interaction, conformational changes occurs firstly in the viral 
gp120 and then, in the transmembrane gp41. Modifications in gp120 structure contribute to 
the exposure of V3 region, which contains the binding site of the viral chemokine receptors 
CCR5 or CXCR4. This latter interaction mediates further modifications in the gp41 structure 
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leading to the exposition of the hydrophobic N-terminal gp41 fusion domain. Then the 
insertion of this fusion domain into the membrane of the host cell allows its fusion with the 
viral membrane (Chan, Fass et al. 1997) (figure 3). 
 
 
The mechanism of HIV-1 entry can be summarized in the following model. After binding of gp120 to 
receptor and coreceptor (step 1-2), gp41 undergoes conformational changes leading to the exposure of 
the fusion peptide and the accessibility of trimeric HR1 and the hydrophobic N-terminal domain, which 
contains the fusogenic region, and the trimeric HR2 domains (step 3). Then, HR1 and HR2 interacts 
together forming a 6-helix bundle leading to the membrane fusion and virus entry (step 4-5). The triple 
stranded coiled-coil structure (step 3), which probably explains its low immunogenicity in human 
patients infected with HIV-1. 
Fig. 3. Representation of the different steps from the viral-host interaction and the viral 
entry after membranes fusion.  
The chemokine coreceptors CCR5 and CXCR4 of HIV are preferentially found in lipid rafts 
(Kozak, Heard et al. 2002). These cholesterol and sphingolipid-enriched microdomains in 
the plasma membrane mirror the optimal lipid bilayer of the virus and provide likely a 
better environment for membrane fusion (Chambers, Pringle et al. 1990; Chazal and Gerlier 
2003). Several inhibitors including T20 (enfuvirtide) have been developed. T20 is a synthetic 
peptide of 36 amino acids which blocks HIV-1 entry by interfering with the formation of the 
six helix bundle formed following the interaction between the trimeric HR1 and HR2 
domains of the transmembrane envelope glycoprotein gp41 (Kilby, Hopkins et al. 1998). 
More recently a selective CCR5 antagonist, named maraviroc or vicriviroc has been 
developed. By blocking gp120-CCR5 interaction this antagonist present a potent anti-HIV-1 
activity (Kromdijk, Huitema et al.; Perry). As T20, maraviroc is also active at nanomolar 
concentrations. It is postulated that CCR5 antagonists may be of great interest, if we 
consider that HIV-1 infection is essentially mediated by CCR5 tropic viruses (Kromdijk, 
Huitema et al.). The use of these type of entry inhibitors has been found to effectively inhibit 
infection of cells in vitro and in vivo by R5 strains tropic HIV-1 that have developed 
resistance to the other major classes of anti-retroviral drugs (anti reverse transcriptase and 
anti protease inhibitors). It is interesting to note that this is the first anti-HIV drug that 
targets the host cells rather than the virus directly. However, one potential limitation of such 
inhibitors is the possible selection and rapid emergence of CXCR4 tropic viruses. In fact, the 
isolation of HIV-1 from patients, who have never received an anti-retroviral therapy, naïve 
for HAART, showed the presence, of R5 tropic viruses in 85% of the cases. These results are 
in agreement with the natural resistance of persons harbouring CCR5delta32 deletion (Dean, 
Carrington et al. 1996; Huang, Paxton et al. 1996; Liu, Paxton et al. 1996; Samson, Libert et al. 
1996). While the early stage of infection was characterized by the predominance of R5 tropic 
viruses, the emergence of viruses with CXCR4 tropism were associated with the late stage of 
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infection (Scarlatti, Tresoldi et al. 1997). The molecular basis of this R5 to CXCR4 switch 
remains to be clarified. CXCR4 strains seem to emerge only in 50% patients who develop 
AIDS (Connor, Sheridan et al. 1997; Scarlatti, Tresoldi et al. 1997). In addition to these two 
selective HIV-1 strains, an intermediate strain named dual tropic HIV-1 strain which use 
indifferently R5 and CXCR4 was also reported in some HIV-1 infected patients.  
The external envelope gp120 is a highly glycosylated protein. Carbohydrates represent 
about 50% of its molecular weight (Fenouillet, Clerget-Raslain et al. 1989). The majority of 
these carbohydrates are of N-type glycosylation. O-glycosylation seems to be rarely present 
in HIV-1 envelope glycoproteins. Viruses use glycosylation as tool to escape immune 
responses, resist to protease degradation, and adopt structural native conformation or to 
bind cellular receptors. By its carbohydrate parts, envelope glycoprotein gp120 recognizes 
and interacts with high affinity (Kd of nM level) with DC-SIGN (Dendritic Cell-Specific 
Intercellular adhesion molecule–3-Grabbing Non integrin) receptor. DC-SIGN is a C-type 
lectin present on the surface of membranes of dendritic and monocyte/macrophage cells 
(Geijtenbeek, Kwon et al. 2000; Geijtenbeek, Torensma et al. 2000).  
Submucosal DC, which normally process and present antigens to immune cells, bind HIV-1 
using C-type lectin essentially at the vaginal mucosa. However this interaction does not 
trigger the conformational changes necessary for the fusion of the virus and DC membranes. 
But virus bound on DC, or internalized by endocytosis, can migrate to regional lymph 
nodes where its target T-helper cells are found. Thus, dendritic cells expressing DC-SIGN 
appear to act as a “Trojan horse” facilitating the spread of the infection from mucosal 
surfaces to lymphatic organs (Geijtenbeek, Kwon et al. 2000; Geijtenbeek, Torensma et al. 
2000; Kwon, Gregorio et al. 2002). 
After entry and uncoating, the viral genome is released into the cytoplasm. This step is 
concomitant with the start of reverse transcription. The resulted dsDNA migrates into the 
nucleus where it is integrated by the viral integrase into host genome. The integration site is 
preferentially located into active genes locus because HIV like many other viruses cannot 
replicate into quiescent/latent cells. This DNA is flanked by two repeated sequence named 
LTRs (Long Terminal Repeats). Following cell activation, the viral DNA is transcribed by 
cellular RNA polymerase II (RNA pol II). Viral transcription is initiated when cellular RNA pol 
II is recruited at the 5’end of LTR provirus. For efficient transcription elongation a 5’end TAR-
hairpin structure named TAR (Tat associated region) element have to be present and bind HIV 
Tat protein. When Tat protein is absent, the initiation can begin but elongation is abrogated 
and/or inefficient. After translation, of viral protein and assembly in cholesterol rich lipid 
rafts, immature virions are released by budding from plasma membrane infected cells. 
1.3 HIV-1 genome transactivation: an essential role of HIV-1 Tat protein  
Once integrated, HIV genome behaves like the host genes and can be transcribed using the 
cellular RNA pol II and host cell machineries in addition to the viral Tat protein. The HIV 
LTR contains proximal core sequence and a distal promoter. The core element is composed 
by the initiator (Inr) and TATA box (TATA). The distal promoter carries enhancer sequences 
that contain two NF-B and three SP1 binding sites that position RNA pol II at the correct 
site for transcription initiation (Peterlin and Trono 2003; Peterlin and Price 2006). 
Downstream the core element, HIV LTR contains a short nascent stem bulged loop leader 
RNA named TAR (Transcription associated Region) (Berkhout, Silverman et al. 1989; Jeang, 
Xiao et al. 1999). HIV Tat protein is known to be the transcriptional activator that binds to 
this TAR RNA structure and HIV transcription mediated by Tat is illustrated in figure 4.  
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The first step of HIV transcription consists of the formation of the pre-initiation complex by RNA pol II 
recruitment to the promoter. The second step consists to clear the promoter by phosphorylation of the 
RNA pol II at serine position 5 of the CTD by cyclin dependent kinase : CDK7 of the TFIIH protein. This 
phosphorylation increases the binding and affinity of human enzyme capping (Brenchley, Price et al. 
2006) that leads to the 5’end capping of nascent RNA transcripts. At this step a pausing of RNA pol II 
occurs by the recruitment of two negatives elongation factors named: DSIF (DRB sensitivity inducing 
factor) and NELF. Finally, productive elongation occurs by the recruitment of P-TEFb. P-TEFb activity is 
tightly regulated by its association with a complex composed by 7SK snRNA and heterodimer 
HEXIM1/2. Tat recruitment of P-TEFb leads to efficient elongation and the obtaining of totally RNA 
transcripts production. 
Fig. 4. Transcription of the HIV genome and implication of its Tat protein. 
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For summary, after PIC formation and clearance of the promoter a pause of RNA pol II 
occurs. Without recruitment of P-TEFb (positive transcription elongation factor b), only 
short RNA transcripts are formed and subsequently aborted. In fact, in absence of Tat, 
transcription is initiated but elongation do not occurs and only short RNA abortive 
transcripts are produced (Peterlin and Price 2006). At a molecular level, P-TEFb can be 
recruited by several mechanisms (figure 4) and notably by HIV Tat protein. Indeed, 
transcription from the HIV-1 LTR is several hundred folds higher in presence of Tat than in 
its absence. So, the question that follows is how can HIV initiate the synthesis of the first 
viral proteins, including Tat protein, in the absence of the latter viral factor essential for an 
efficient elongation ? Or how the first Tat molecules are synthetized ? 
Several studies have demonstrated that, in HIV, LTR transcription can be separated in two 
steps, the first is Tat independent whereas the second is Tat dependent. Recent studies from 
Greijtenbeek et al. and Gringhuis, van der Vlist et al.(Greijtenbeek et al. 2000; Gringhuis, 
Van der vlist et al. 2010) have shown that HIV can activate initiation and elongation by two 
separate mechanisms. The first, transcription initiation, is activated in endosomal structure 
following the HIV RNA-Toll Like Receptor 8 (TLR8) interaction. More precisely, HIV 
ssRNA-TLR8 interaction induces activation of NF-B p65 and RNA pol II phosphorylation 
at serine 5 residue leading to the recruitment of CDK7 to the transcription units. In parallel, 
they have also shown that elongation depends upon gp120-DC-SIGN interaction. This 
membrane interaction activates elongation by phosphorylation of serine 276 and serine 5 of 
NF-B p65 and RNA pol II respectively and their recruitments with CDK9 to the HIV LTR. 
This mechanism can explain how the HIV initiates the production of the first HIV-Tat protein. 
Then, Tat proteins take over and amplify viral transcription by its capacity to bind the 7SK 
small nuclear RNA (7SK nRNA) complex and recruits P-TEFb to the paused RNA pol II, by 
interacting cooperatively with TAR element. This interaction is mediated by Tat arginine rich 
motif. Once recruited to the transcription units, P-TEFb phosphorylates NELF (negative 
elongation factor) and the CTD of RNA pol II at serine 2 residue. Tat has also been reported to 
interact with many factor/co-factor implicated in transcription as: Sp1, TATA box binding 
protein, CDK2, CBP/p300, TFIIH and RNA pol II. Overall, Tat permits an efficient elongation 
and co-transcriptional processing by splicing and polyadenylation machineries. When levels of 
the regulatory Tat protein fall to below threshold levels, HIV becomes latent. 
1.4 HIV-1 infection and its effects on immune and the central nervous system 
1.4.1 Natural history of HIV-1 infection 
The course of HIV infection could be divided into three distinct clinical phases: acute 
infection, asymptomatic stage or chronic infection and symptomatic stage characterized by 
AIDS development (Furrer, Opravil et al. 2001) (figure 5).  
The first step called acute phase corresponds to the contamination, the primary viral 
replication and the beginning of immune sensitization. The most common routes of HIV 
infection are mediated by sexual transmission of the virus, transfusion by contaminated 
blood products, the use of unsafe needles by drug users, and perinatal transmission from 
infected mother to infant. This latter case of HIV transmission can occur either in utero or 
during breast-feeding (Coovadia, Rollins et al. 2007). Cases of contamination during 
delivery are also reported. Early after exposure, the virus reaches some strategic organs 
such as the secondary lymphoid organs (mucosa-associated lymphoid tissue and gut-
associated lymphoid tissues), which content most of the cells targeted by HIV. At this stage, 
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the virus replicates actively during a period of 6 to 12 weeks called the acute phase. Viral 
load reaches several millions copies of viral RNA per millilitre (ml) of plasma. T cells are 
depleted in blood and the gastro-intestinal tract, but the pool of T cells present in the blood 
compartment was restored by the central lymphoid organs. In general this step remains 
asymptomatic, but some patients could develop signs of of routine infection including, 
fever, lymphadenopathy and rash (Quinn 1997). These symptoms may last in general two to 
three weeks. At this stage of infection, the innate and adaptive immune 
systems react strongly to control HIV replication to lower the viral load to a set point often 
below 20000 RNA copies per ml of plasma (figure 5).  
 
 
A generalized graph that represent the relationship between T cells number by blood microliter (blue 
line) and HIV viral RNA copies by blood ml (red line) over the time course of untreated HIV infection. 
Two major mechanisms involved in T cells dysfunction and progression toward AIDS are represented 
(arbitrary units) such as increase in pro-inflammatory factors TNF-ǂ, IL-6, IFN-ǂ (pink line), and 
upregulation of immunosuppressive factors including IL-10, PD-1, PD-L1 and IDO (green line).  
Fig. 5. Evolution of T cell count and viral load over the different stages of untreated HIV 
infection.  
The second stage is an asymptomatic phase where the virus persists and the infection 
becomes chronic. During this period, that varies from 6 months to several decades 
depending on the patients, the virus replicates continuously mainly in the reservoir cell  
such as macrophages, the nervous system and regulatory T cells (Treg) (Tran, de Goer de 
Herve et al. 2008). During this phase, most of the patients maintain a normal CD4 T cell 
count with apparent normal health. The immune system is still continuously activated 
against viral replication but HIV will escape to this immune pressure by different 
mechanisms including the emergence of new variants. One of the most dramatic viral 
emergence is the appearance of X4 and dual tropic R5/X4 viruses, which replicate more 
rapidly, produces high amount of viruses progeny and are more cytopathic (Schuitemaker, 
www.intechopen.com
 HIV-Host Interactions 
 
34
Koot et al. 1992; Connor, Sheridan et al. 1997; Singh and Collman 2000). In fact, a loss of 
CD4+ cells of about 30 to 60 cells per microlitre and per year was observed in HIV-1 infected 
patients (figure 5). This asymptomatic phase has duration of 6 to 10 years and may be 
greatly modulated by highly anti-retroviral therapy (HAART). However in less than 1% of 
HIV-1 infected patients this asymptomatic phase is highly reduced (1 to 2 years), and can 
last longer, more than 25 years, in patients under HAART (Markowitz, Mohri et al. 2005). In 
addition to the direct lyses of infected cells this phase is accompanied with several immune 
disorders leading to immune exhaustion.  
One hallmark of this immune disorder is chronic immune activation characterized by 
increase production of pro-inflammatory cytokines such as TNF- and IL-6. TNF-ǂ, thus, 
lead to the activation of HIV replication, loss of CD4 and CD8 through apoptosis (Said, 
Dupuy et al. 2010) and to neuronal disorders including HIV associated dementia (Nixon and 
Landay 2010). Increase of IL-6 production has been associated with immunological 
disorders including B cell lymphoma and hypergammaglobulinemie. It is interesting to note 
that Tat protein is able to induce TNF-ǂ and IL-6. Production of these two cytokines has also 
been correlated with a systemic increase of bacterial products such as LPS. Indeed Brencley 
et al., (Brenchley, Price et al. 2006) have shown that chronic phase of HIV infection is 
characterized by an increase in circulating bacterial products related to the damage of the 
intestinal epithelium by the HIV-1 cytopathic effect. Released viral antigens and bacterial 
products contribute to the constant persistence of a chronic immune activation and T cells 
death. Other mechanism involved in immune activation is mediated by IFN-ǂ produced by 
plasmacytoïd DC (pDC), a particular DC population specialized in antiviral immunity. It 
was reported that HIV induce IFN-ǂ production by pDC through the activation of TLR7 by 
viral ssRNA. This cytokine acts on CD4+ and CD8+ lymphocytes to induce an activated 
phenotype (CD69+, CD38+) and will in turn lead to T cell apoptosis (Martinson, Montoya et 
al. 2010). This great and continual immune activation fails, however, to contain HIV 
infection. This phenomenon could be explained by the upregulation of several 
immunosuppressive factors that impaired T cell responses. Among those, it has been 
reported an a) increase in the production of the immunosuppressive cytokine IL-10, 
principally by monocytes cells; b) increase expression of programmed death 1 (PD-1) on 
monocytes (Said, Dupuy et al. 2010), LT CD4+ and LT CD8+, and its ligand PD-L1 on 
monocytes, macrophages, mDC and pDC. Subsequently, PD-1/PD-L1 interaction stimulates 
IL-10 production, induces negative signals for TCR activation and leads to T cell death; c) 
enhancement in the activation of the immunosuppressive enzyme indoleamine 2,3-
dioxygenase (IDO) in mDC and pDC which acts by depleting the essential amino acid 
tryptophan and inhibits T cell proliferation and d) increase in the generation and activation 
of T reg, a subset of T lymphocytes with immunosuppressive activity. All of these 
immunosuppressive factors will contribute to immune inactivation and have been 
associated with disease progression to AIDS. As the CD4+ cell count drops below 200 
cells/mm3 the risk of developing opportunistic infections including pneumocystis carini, 
CMV, JC or malignancies increases Kaposi’s sarcoma (Clifford and Demierre 2005; Bonnet, 
Balestre et al. 2006). Advanced HIV-disease is characterized by a strong T CD4 depletion to 
less than 50 cell/mm3, high viral load and multiple opportunistic infections and 
malignancies. 
AIDS represents the final stage of HIV-1 infection and is characterized by a profound 
depletion of CD4 positive T cells. In fact, after several years of unresolved chronic infection, 
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the rate of CD4+ T cells drops dramatically in the blood to a critical rate of 200 T CD4 cells 
microliter. This phase is characterized by the occurrence of several rare opportunistic 
infections. The first opportunists that are taking advantage of immunocompromised patients 
are oral candidiasis, pneumococcal infections, mycobacterial infections and reactivation of 
herpes simplex and varicella virus. AIDS is also associated with tumor proliferations such as 
Kaposi's sarcoma, due to Human Herpes Virus 8 (HHV8), lymphoma associated with Epstein-
Barr virus and cervical and anal carcinoma associated with human papilloma virus. In fact, 
this stage results in an extreme immunosuppression with diverse clinical features including 
opportunistic infections, malignancies and neurological disorders (So, Holtzman et al. 1988; 
Coopman, Johnson et al. 1993; Simpson and Tagliati 1994) and without treatment will 
irremediably lead to death of the patient within a few months. 
1.4.2 Neuropathogenesis of HIV-1 infection 
In addition to its tropism for the cells of the immune system, HIV is also known for its 
neurotropism. The virus is early found in the CNS carried by infected cells essentially 
macrophages. The virus can be directly isolated and cultured from the cerebrospinal fluids 
(CSF) from HIV-1 infected patients. In the CNS the virus replicates strongly in macrophages 
and microglia and moderately in astrocytes. Although HIV-1 is qualified as a neurotropic 
virus, it does not infect neurons. Consequently to CNS infection, about 60% of HIV-1 
infected patients showed HIV associated neurological, which includes dementia and 
neuropsychiatric and cognitive motor impairments (Ozdener 2005; Giunta, Obregon et al. 
2006). Infiltration of the virus in the brain is concomitant with the development of 
astrocytosis and microgliosis. While HIV-1 productively replicates in macrophages and 
microglia, infection of astrocytes allow only, the expression of early proteins Rev, Tat and 
Nef (Tornatore, Nath et al. 1991; Lipton and Gendelman 1995; Kutsch, Oh et al. 2000). It is 
interesting to note that astrocytes function also as an reservoir for HIV-1. Neuronal injury 
observed in the CNS of HIV-1 infected patients results from the activation direct by the 
virus or indirectly by inflammatory neurotoxins. For example it has been shown that the 
infection of astrocytes allowed to the impairment of the uptake and secretion of glutamate 
and to the modulation of glutamate receptor expression (Bezzi, Carmignoto et al. 1998). It 
was also demonstrated that, by its Tat protein, HIV stimulates the production of various 
chemokines including MCP-1, IL-8 and IP-10 which participate in the recruitment of 
macrophages and various type of leukocytes (Conant, Garzino-Demo et al. 1998; Kutsch, Oh 
et al. 2000). Production by HIV-1 infected macrophages of neurotoxins including quinolate, 
glutamate and L-cysteine, and inflammatory mediators including, IFN-, IFN- IL-6, IL-1, 
IL-1, TNF-, and TNF- play an essential role in HAND. The loss of neurons in HAND by 
apoptosis and other mechanisms is directly related to these release of toxic mediators by 
activated and infected cells (Zink, Zheng et al. 1999). Tat, Nef, Vpr, gp120 and gp41 have 
been described as directly implicated as neuropathogenic factors. By acting with CXCR4, 
gp120 induces apoptosis of neurons. Also by acting on voltage gated calcium channels and 
N-methyl-D-aspartate receptor (NMDAR) gp120 induces calcium mobilization which 
mediates the production of reactive oxygen species (ROS), apoptosis and various neurotoxin 
mediators (Medina, Ghose et al. 1999). As gp120, HIV-1 Tat protein has been reported to be 
implicated in neuron injury directly via apoptosis (Sabatier, Clerget-Raslain et al. 1989; Shi, 
Raina et al. 1998; Nath, Haughey et al. 2000) and indirectly via the induction of 
inflammatory cytokines including TNF-and IL-1.  
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1.4.3 HIV and Kaposi’s sarcoma: Effect of Tat protein  
The high incidence of Kaposi’s sarcoma (KS) in patients with HIV-1 infection has been 
related to the co-infection with HHV-8 also named KSHV (Kaposi sarcoma-associated 
herpes virus) (Schulz, Arbusow et al. 1998; Sirianni, Vincenzi et al. 1998; Aoki and Tosato 
2004). It was shown that the presence of KSHV alone is not sufficient for KS development. 
The presence of HIV-1 seems to be essential for the development of KS lesions. This 
observation is in agreement with the drastic decrease of KS in patients under HAART. The 
analysis of the HIV-1 viral factor implicated underlined the essential role of Tat protein 
which acts as a transactivator factor for KSHV lytic cycle and activates proliferation, MAP-
kinase activation, angiogenesis and tumoregenesis. It was shown that Tat promotes the 
tumorogenesis of endothelial cells both by acting at different ways by: stimulating the 
production of -FGF, recruiting VEGF-2 receptor, both on KS and on endothelial cells, 
whose stimulation is essential for VEGF angiogenic effects (Albini, Benelli et al. 1996; Albini, 
Soldi et al. 1996; Ganju, Munshi et al. 1998), blocking apoptosis, and stimulating KSHV 
replication (Pyakurel, Pak et al. 2007). In addition Tat is able to stimulate the production of 
inflammatory cytokines following its interaction with chemokine receptors.  
1.4.4 HIV and immunological disorders  
From the asymptomatic stage and before T CD4 lymphocyte depletion, a generalized immune 
depression is observed in HIV-1 infected patients including disorders of both in the 
specific/acquired and innate immunities. This immunodepression in HIV-1 infected patients is 
associated with a profound alteration of the cytokine production (McMichael, Borrow et al. 
2010; Clerici and Shearer 1993; Fauci 1996). These alterations have effects on target cells and 
influence also the virus replication. Increased production of pro-inflammatory cytokines 
stimulates HIV-1 replication via the activation of NF-B pathway. In fact the LTR promoter of 
HIV-1 contains NF-B binding sites. HIV-1 infection is associated, since the asymptomatic 
stage with a chronic immune activation and dysfunctional cytokine production. The acute host 
response to primary HIV-1 infection is characterized by Th0 cytokine profile, including the 
pro-inflammatory cytokines IL-1, IL-2, IL-6, TNF-, IFNand IFN- as well as the anti-
inflammatory cytokines IL-4, IL-10 and IL-13 (Harrich, Garcia et al. 1989; Hatada, Saito et al. 
1999). At later stages of infection with disease progression, the pattern of cytokine production 
shifts toward a strongly based Th2 response mediated by IL-4, IL-6 and IL-10 (Rinaldo, 
Armstrong et al. 1990; Graziosi, Gantt et al. 1996; Takizawa, Ohashi et al. 1996). This profile 
was revealed inefficient to eradicate the virus. The mechanism of HIV induced cytokine 
production has been largely studied. There are many HIV-1 proteins that are capable of 
inducing the production of several cytokines. These proteins include HIV-1 glycoprotein 
gp120 that induce the secretion of many pro-inflammatory cytokines including IL-1, IL-6, IL-8, 
TNF-, and IFN- (Francis and Meltzer 1993; Ameglio, Capobianchi et al. 1994; Ankel, 
Capobianchi et al. 1994; Capobianchi, Barresi et al. 1997). Interestingly, gp120 is also able to 
induce the secretion of IL-4 and IL-13 in basophils and IL-10 in mononuclear cells. Nef protein 
is able to induce the production of IL-1, IL-6, IL-10, IL-15, TNF- and IFN- in various human 
leukocyte populations (Schols and De Clercq 1996; Patella, Florio et al. 2000). There is also 
evidence that Vpr induces the expression of IL-6, IL-8, IL-10, TNF- and IFN- in a variety of 
cell types (Brigino, Haraguchi et al. 1997). 
Another HIV-1 protein, Tat, is known to stimulate the production of many cytokines and 
chemokines including IL-1, IL-2, IL-6, IL-8, IL-10, TNF- and MCP-1 (Clerici and Shearer 
1993; Moore, O'Garra et al. 1993; Badou, Bennasser et al. 2000; Nath, Haughey et al. 2000; 
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Bennasser, Badou et al. 2002; Bennasser and Bahraoui 2002; Contreras, Bennasser et al. 2005). 
Our laboratory has shown that HIV-1 Tat protein induces the production of IL-10, a highly 
immunosuppressive cytokine by human peripheral blood monocytes. Since IL-10 levels 
have been shown to progressively increase as the disease progresses toward AIDS, one can 
hypothesize that this event can play a crucial role in the immune deregulation observed 
during HIV-1 infection. In line with this hypothesis, Shearer’s group in a study including 
more than 1000 patients identified four patient classes depending on the capacity of their 
CD4 T lymphocytes to respond to different stimuli (mitogen, alloantigen, influenza virus, 
and HIV antigens). The progressive loss of the response of the immune system to these 
stimuli was found to be associated with a course leading to AIDS. Considerable production 
of IL-10 by peripheral blood mononuclear cells was observed in these patients and 
paralleled the alteration in CD4 T cell proliferative function. In addition, the 
immunosuppressive effect of IL-10 also correlated with the restoration of the capacity of 
isolated mononuclear cells of patients infected by HIV and immunodepressed to proliferate 
in vitro after stimulation by peptide antigens of HIV-1 envelope glycoprotein in the presence 
of a neutralizing anti-IL-10 antibody (Clerici, Wynn et al. 1994). In another study, Stylianou 
et al. evaluated the level of IL-10 in the sera of HIV-1 infected patients at different stages of 
infection. In agreement with Shearer’s conclusion, they showed an increase in IL-10 level 
with disease progression. They also showed a decrease in IL-10 level in patients under 
highly active retroviral therapy (HAART). Inversely, it was reported an increase of IL-10 
levels in patients with failure in tri-therapy treatment. Similarly low level of IL-10 was 
observed in HIV-1 long term non progressors or elite controllers (Clerici, Wynn et al. 1994). 
Inversely, it was showed that the persistence of a great level of IL-10 in the sera correlates 
with the failure in HAART (Stylianou, Aukrust et al. 1999). 
HIV-1 infection affects cellular signaling. The two most important signaling pathways 
involved in cytokine production include the PKC and calcium pathway (figure 6). These 
pathways are activated after ligand-receptor interaction. Subsequently, this interaction 
activates phospholipase C which then cleaves its substrate PIP2 (phosphoinositol 
biphosphate) in IP3 (inositol 1,4,5-triphospate), responsible of the mobilization of 
intracellular calcium and to DAG (diacylglycerol), which initiates PKC activation. These two 
pathways lead to the phosphorylation and activation of cellular proteins mitogen-activated 
protein (MAP) kinase and of transcriptional factors including NF-AT, NF-B, CREB and AP-
1 responsible for the induction of cytokine genes (Spitaler et Cantrell 2004). In our 
laboratory we have accumulated several data showing the mechanism recruited by Tat 
protein to stimulate the production of the highly immunosuppressive cytokine IL-10. In the 
following part we will describe the role of Tat protein at different levels including its 
structure, secretion and uptake, mode of action for the transactivation of HIV-1 
transcription, activation of signaling pathways and in the conclusion we will discuss Tat as 
potential target for drug or vaccine development. 
2. HIV Tat protein  
2.1 Background 
HIV Tat protein is one of HIV conserved protein. It is early produced after HIV infection. 
Tat is a 9-14 kDa protein encoded by two exons separated by a non coding region. The first 
exon encodes the 72 first amino acids (figure 7). The length of HIV-1 Tat protein ranges from 
86 to 101 amino acids and consists of 130 amino acids for HIV-2 (Johri, Mishra et al. 2011). 
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The 101 amino acids form of Tat is predominant in clinical isolates. Another form that 
comprises 86 amino acids is also found in some subtype B isolates and in the laboratory 
strain HXB2. The Tat sequence can be subdivided into six functional domains including N-
terminal a proline and cysteine rich region, an hydrophobic core, a basic region followed by 
a glutamine rich region and a C terminal domain that contain a tripeptide RGD (Arginine, 
glycine, aspartatic acid) (figure 7). In addition, a domain containing the basic region is also 
called protein transduction domain (PTD), which renders Tat to have the ability to cross cell 
membranes and to be used as vector for gene transfer. Thus, viral Tat protein can be either 
intracellular or extracellular. The main function of HIV Tat protein is to transactivate the 
HIV long term repeat for retroviral transcription. 
 
 
External stimulus activates a G protein coupled receptor, which activates a stimulating G protein. This 
G protein activates phospholipase C (PLC), which cleaves phosphoinositol-4,5-biphosphate (PIP2) into 
1,2 diacylglycerol (DAG) and inositol-1, 4, 5-triphosphate (IP3). The IP3 interacts with calcium channel 
in the endoplasmic reticulum (ER), releasing calcium (Ca2+) into the cytoplasm. Intracytosolic calcium 
can interact with calmoduline proteins. This, leads to the activation of CAM kinases and calcineurine. 
Activation of CAMK and calcineurine induce activation and nuclear translocation of CREB and NF-AT 
respectively. In other hand, the increase in calcium levels activates PKC, which translocates to the 
membrane, anchoring to DAG and phosphatidylserine. Active catalytic PKC then, phosphorylate 
targets such as Rac, Raf that lead to downstream activation of MAP kinases and NF-B and AP-1 
transcription factor. 
Fig. 6. The Protein Kinase C and calcium pathways. 
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Tat is encoded by 2 exons in the HIV genome and it is composed by several regions. N-ter region 1-21 is 
a rich proline region. A region implicated in HIV transactivation is the 21-37 amino acids cysteine rich 
region and the core region 38-48 implicated in the Tat binding of HIV RNA. The basic rich region 49-59 
is involved in Tat internalization whereas the glutamine rich region 60-72 in HIV replication. Finally the 
last region with the RGD sequence is encoded by the second exon. 
Fig. 7. Organization of HIV-1 Tat protein: primary amino acids sequence and different 
domain of Tat.  
2.1.1 HIV-1 Tat structure 
Few studies have been devoted to studying secondary and tertiary structure of Tat protein. 
It seems clear that Tat belongs to the family of intrinsically unstructured proteins (Foucault, 
Mayol et al. 2010; Bayer, Kraft et al. 1995). Circular dichroïsme studies of Tat (analyze of 
secondary structure) showed a majority of -turns structure and the absence of -helical and 
-sheets structures when the spectra were performed in aqueous solutions. However about 
20 to 50% of alpha helical structures were detected when the protein was analyzed in 
organic solvant. Tertiary studies with using NMR confirmed that HIV Tat was generally an 
unfolded protein (Bayer, Kraft et al. 1995; Shojania and O'Neil 2006). They also 
demonstrated that the cysteine and basic regions are highly flexible and the N-terminal 
region is localized between the hydrophobic core and the glutamic rich domains (Watkins, 
Campbell et al. 2008). The X-ray cristallographic determination of Tat structure is not 
available. In summury all the available data indicated that Tat contains no ordered -helical 
or -sheet structures. Thus the biological active Tat protein seems to be conformation 
independent and perhaps only a limited gain of structure is necessary for its function. All 
these studies suggest that Tat protein does not have a defined secondary or tertiary 
structures and that biological active Tat protein is natively unfolded and only a limited gain 
of structure is necessary for its function. 
2.1.2 HIV-1 Tat secretion and internalization 
Despite the importance of extracellular Tat, few studies have focused on its mechanism of 
secretion from infected cells and its entry into uninfected cells (Rayne and Debaisieux et al. 
2010; Vendeville and Rayne et al. 2004) (Westendorp, Frank et al. 1995). In fact, HIV Tat 
protein does not have a signal sequence and seems to be secreted by infected cells by an non 
conventionnal pathway. It is found present in the sera of HIV-1 infected patients at the 
nanomolar level (Ensoli, Buonaguro et al. 1993; Xiao, Neuveut et al. 2000) a value which 
may be underestimated since Tat may be trapped by its potential receptors, and particularly 
the heparan sulfates which are largely expressed on cell surfaces. Thus, the concentration of 
Tat, in vivo, is probably higher in the vicinity of the active HIV replication sites. After its 
secretion, Tat protein is taken up by neighboring cells infected or not. Despite the previous 
data reporting a particular mechanism for Tat uptake, it is clear now, that Tat protein enter 
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viable cells essentially by endocytosis. This entry is mediated by the basic domain of Tat, 
also named PTD (protein transduction domain) and used for the development of peptidic 
vectors (Futaki and Suzuki 2001). 
2.2 Tat activates the production of IL-10 in human monocytes 
Our group has shown that HIV-1 Tat protein, by acting at cell membrane level, induces the 
production of IL-10, by non infected human monocytes (Badou and Bennasser 2000; 
Bennasser and Bahraoui 2002). To this end monocytes from healthy donors were purified 
and stimulated during 24 hours with increasing concentrations of recombinant Tat protein. 
Results showed that Tat protein induced strong and dose dependent IL-10 production. In 
contrast in the absence of Tat no IL-10 production was observed. This Tat induced IL-10 
production persists after 48 and 72 hours of Tat stimulation. The amount of IL-10 produced 
by monocytes in response to Tat is dose and stimulation time dependent. Specifity of Tat 
effect was demonstrated by showing that chemically modified Tat, after H2O2 oxidation, 
becomes unable to stimulate IL-10 production. The specificity of Tat effect was further 
demonstrated by showing that when the stimulation of monocytes was performed in the 
presence of anti-Tat antibodies, IL-10 production by monocyte was totally inhibited (figure 
8). 
 
 
Tat 1-86 at 10 and 100 nM were incubated with or without anti-Tat antibody 2.5 g/mL or were 
oxidated by H2O2 treatment. After 1 hour treatment, Tat treated or not, was incubated with human 
primary monocytes for 24h. IL-10 production was measured by ELISA.  
Fig. 8. HIV-1 Tat induces specifically IL-10 production by human monocytes. 
To determine the active domain of Tat that is responsible for the activity of Tat, monocytes 
were stimulated with GST-Tat deleted mutants including GST-Tat 1-72 (deleted form RGD 
domain), GST-Tat 1-55 (deleted from RGD and glutamate domains), GST-Tat 1-54 (deleted 
from RGD and basic domains), GST-Tat 20-72 (deleted from the N-Terminal domain), and 
GST-Tat 30-72 (deleted from de N-Terminal domain). Only GST-Tat deleted mutants but 
containing the N-terminal domain continues to stimulate IL-10 production. While the 
deleted mutants GST-Tat 20-72 and GST-Tat 30-72 as GST alone were unable to stimulate IL-
10 production (figure 9). These data underlined the importance of the N-Terminal domain in 
IL-10 Tat induced activity.  
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Monocytes were treated with 1 and 10 nM of wild type GST-Tat 1-101 or deleted mutant of Tat or GST 
alone as negative control. After 24 h of stimulation IL-10 production was measured by ELISA. 
Fig. 9. The N-terminal domain of Tat : 1-45 is sufficient to induce IL-10 production by 
human monocytes. 
As previously demonstrated in different report Tat protein is able to enter cells and to 
localize in the nucleus. So Tat protein is able to activate IL-10 production by acting at the cell 
membrane level or inside the cell. To understand its mechanism of action during the first 
steps of the activation, Tat protein was immobilized by coating in wells before adding 
purified human monocytes. In this condition, immobilized Tat leads to a dose dependent 
production of IL-10 indicating that Tat mediates its action by acting at the cell membrane. 
These results are in line with the capacity of the Tat deleted mutant, GST-Tat 1-45, to 
stimulate IL-10 production. In contrast to native Tat protein, the deleted mutant GST-Tat 1-
45 is unable to penetrate into cells because it lacks the basic domain, responsible for 
penetration and nuclear localization of Tat.  
The specific receptor implicated in this interaction remains to be characterized, despite the 
fact that different regions of Tat have been implicated in interaction with various receptors: 
the N-terminal region with CD26 receptor (Gutheil, Subramanyam et al. 1994), the tripeptide 
RGD with integrins v3 and 51 of DC, and the basic region with membrane lipids and the 
VEGFR of endothelial cells (Rubartelli, Poggi et al. 1998). Other reports, demonstrated the 
interaction of the cysteine rich region of Tat 24-51 with CCR2, CCR3 and CCR5 chemokine 
receptors and the heparan sulfate proteoglycans (Johri, Mishra et al. 2010; Ensoli, Buonaguro 
et al. 1993). It has been proposed that Tat could interact with the coreceptor CXCR4 and thus 
competitively inhibit infection by X4-tropic HIV-1 strains (Xiao, Neuveut et al. 2000). In this 
way, Tat contributes to immune system disorders as it induces apoptosis of T-lymphocytes, 
inhibits MHC class I expression, alters cell activity by blocking L-type channels (Li, Li et al. 
2009).  
Using chemical inhibitors and molecular analysis, we showed that Tat-cell interaction lead 
to activation of different signaling pathways including PKC. In fact, the PKC pathway, one 
of the major pathway involved in the production of cytokines, plays an essential role in this 
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induction. Downstream PKC, activation of MAP kinases and NF-B pathways by Tat is 
crucial for Tat induced IL-10 (Bennasser and Bahraoui 2002; Leghmari and Bennasser 2008; 
Leghmari and Bennasser 2008; Contreras 2008). 
2.3 Analysis of the activated signaling pathways 
Calcium and PKC pathways are activated following the action of the phospholipase C 
(PLC). Implication of PLC signaling in the production of IL-10 following Tat activation was 
evaluated by using U73122, an inhibitor of PLC. In the presence of this inhibitor a strong 
inhibition, more than 50% of the production of IL-10 by Tat was observed. Thus, the 
activation of PKC signaling pathways known to induce the expression of cytokine genes 
was further investigated.  
2.3.1 Tat activates PKC pathway 
2.3.1.1 The PKC pathway 
The PKC belongs to the serine/threonine kinase family. It represents a key element 
recruited to regulate cell responses to external stimuli. Eleven PKC isoforms have been 
identified and classified into three groups based on their ability to be activated by Ca2+ and 
DAG (Spitaler and Cantrell 2004). The classical PKC- and -, isoforms are activated 
by Ca2+ and DAG, the novel PKC-ǉ, -ǈ, -δ and -, are Ca2+ independent but DAG dependent, 
finally the atypical PKC and - (also named - in murine cells) are Ca2+ and DAG 
independent (Lee, Duan et al. 2008) (figure 10). PKC are single polypeptide chains of 
heterogeneous size, ranging from 67.2 kDa for PKC to 83.5 kDa for, PKC. Each PKC 
isoform is the product of a separate gene, except for PKC- and PKC-which are 
alternative spliced variants of the same gene. At the structural level, PKC contained four 
conserved domains (C1 to C4) (figure 10) and five variable regions (V1 to V5) that encode 
isoform-specific properties. The conserved region mediates binding to the activating 
cofactors: C1 for DAG or to PMA when used as pharmacological tool, and C2 for Ca2+. 
2.3.1.2 Effects of HIV-1 Tat on PKC pathway 
The implication of PKC pathway in the control of IL-10 production mediated by Tat was 
analyzed by complementary approaches. Pre-treatment of cells with Ro31-8220, an inhibitor 
of all PKC isozymes inhibits totally Tat induced IL-10, thus demonstrating the crucial role of 
PKC pathway. In agreement with the essential role of PKC pathway, Tat becomes unable to 
stimulate IL-10 production in monocyte previously treated during 48h with PMA. In order 
to understand the nature of PKC isoforms activated by Tat and essential for IL-10 
production, monocytes isolated from healthy donors were cultured in the presence of Tat at 
10 or 100nM and cytoplasmic and membrane proteins were isolated after 30 min or after 1 or 
2 hours. Whereas PKC is localized in the cytoplasm in unstimulated human monocytes, Tat 
stimulation induces in a dose dependent manner, PKC translocation to the membrane 
indicating PKC activation. This activation observed after 30min of Tat stimulation reaches a 
peak in 1h and decreases after 2 hours of stimulation. Thus HIV-1 Tat induces PKC 
activation in a dose and time dependent manner in human monocytes. To investigate the 
involvement of PKC activation in Tat-induced IL-10 production, monocytes were incubated 
with different PKC inhibitors. Ro318220 as well as Gö6983 which inhibits several PKC 
isoforms including PKC (IC50= 7 nM), PKC- (IC50 = 6 nM), PKC- (IC50 = 10 nM), 
PKC-(IC50= 60 nM) and PKC- (IC50 = 20 M) totally inhibit IL-10 production (Bennasser 
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and Bahraoui 2002; Leghmari and Bennasser 2008; Contreras 2008). Gö6976 which inhibits 
classical PKC isoforms - and - has no effect on the capacity of Tat to induce IL-10 
production by monocytes. Altogether, these results suggest that PKC isoforms - -and 
 are not primarily involved in the signaling pathways implicated in IL-10 production. To 
evaluate the implication of PKC-and  two other inhibitors were used. Hispidin, PKC- 
and  inhibitor (IC50 = 20 M), and rottlerin, an inhibitor of PKC-(IC50 = 3-6 M). 
Hispidin used at 2-20 M inhibits IL-10 production by Tat in a dose dependent manner, an 
inhibition of 60% is reached in the presence of 20 M of Hispidin. The implication of PKC- 
in IL-10 production was further evaluated by using rottlerin 5-30 M. In these conditions an 
inhibition reaching 90% was observed. Interestingly, PKC- and PKC inhibitors used 
separately at 2 and 5 M inhibited IL-10 production induced by Tat by 15 and 45% 
respectively, but when used in combination, they inhibited IL-10 production by 85% thus 
suggesting a possible synergistic effect between these two PKC isoforms (Bennasser and 
Bahraoui 2002). 
 
 
The three subgroups of PKC have been identified and their regulatory domains identified. The classical 
PKC isoforms (cPKC) share all typical regulatory features: the autoinhibitory pseudosubstrate motif, 
two DAG-binding C1 domains (C1a and C1b) and the calcium-binding C2 domain. Novel PKC isoforms 
(nPKC) lack a calcium-binding motif but contain an extended N-ter domain that can receive regulatory 
signals. They are regulated by DAG. The catalytic activity of atypical PKC isoforms (aPKC) is 
independent of DAG and calcium, and they seem to be regulated by regulatory proteins in association 
with the nuclear localization signal (NLS) and nuclear export signal (NES) in their regulatory domain 
Fig. 10. Primary structure and identification of the different PKC family and their functional 
domains adapted from Spitaler et Cantrell 2004.  
After ligand-receptor interaction on the cell surface, phospolipids are hydrolyzed by PLC, 
producing DAG and IP3 both acting as second messengers. Subsequently, DAG activates 
PKC, which in turn phosphorylates a range of cellular proteins. More precisely activation of 
PKC is mediated by phospatidylserine (PS) binding domain that includes C2, the basic 
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pseudosubstrate peptide, and the cysteine rich region that contributes to the increased 
affinity of PKC to PS by interacting with DAG. These PS binding domains have also been 
reported to be involved in affinity, PKC localization, membrane translocation and binding to 
potential receptors. In resting cells, PKC is localized in the cytoplasm in an inactive form 
where the pseudosubstrate sequence upstream from C1 binds to the catalytic domain, but 
cannot be phosphorylated since it lacks a phospho-receptor amino acid. Upon activation, 
Ca2+ and or phosphoinositides induce a conformational change leading to the release of the 
pseudosubstrate. Thus the catalytic site becomes accessible to anchoring proteins called 
RACK (receptor for activated kinase) or substrates STICK (substrate that interacts with C-
kinase). This PKC activation is accompanied by a translocation from the cytoplasm to the 
membrane. Subsequent to membrane translocation and PKC activation, a second messenger 
seems to be stimulated and leads to the phosphorylation of PKC binding proteins thus, 
reducing their affinity for PKC and PS. 
 
In the cytoplasm, PKC is present as an inactive form. After its activation by phosphorylation, it 
undergoes conformational modifications leading to its translocation from the cytoplasmic to the 
membrane compartment. In membrane compartment, PKC associates with a second messenger DAG 
(and in the case of classical PKC isoforms, calcium) produced after receptor stimulation. Binding to the 
second messengers is also required for the release of the pseudosubstrate motif from the active site to 
give an active enzyme. 
Fig. 11. Activation of PKC pathway  
We next investigated which isoforms of PKC are activated by Tat protein. Monocytes were 
incubated with Tat at 10 nM for 15, 30 min or 1 hour and PKC localization was analyzed by 
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western blot using specific antibodies. Results showed that as soon as 15 min Tat induces 
translocation to the membrane of four PKC isoforms: PKC-, PKC-, PKC-, and PKC-. 
To further analyze the implicated PKC isoforms in Tat induced IL-10 production, these PKC 
isoforms activated by Tat were targeted with isoform specific antisense oligonucleotides. 
Monocytes were pre-incubated during 24 hours with PKC-, PKC-, PKC-, and PKC-or 
with the corresponding sense sequences as negative controls. After 24h monocytes were 
stimulated during 1h by Tat at 10 nM and then the level of each isoform in the cytoplasmic 
and membrane compartments were determined by western blot (Bennasser and Bahraoui 
2002). Treatment with 5 M of PKC- antisense oligonucleotide down regulates PKC- 
expression and the use of 15 M oligonucleotide totally inhibits PKC- expression. The use 
of antisense PKC- inhibits specifically PKC-, since PKC-is still detected in the same 
monocytes and is activated by Tat at 10 nM (figure 12). The same specificity of inhibition  
 
 
Monocytes were treated with sense or antisense oligonucleotides (5, 15 M) specific for PKC- PKC-
 PKC- PKC-fter washing, cells were stimulated with HIV-1 Tat protein at 10 nM for 1 hour. 
Isoform specific PKC inhibition was assessed by western blot (bottom). IL-10 production was measured 
by ELISA 24h later (Sirianni, Vincenzi et al. 1998). In each case, specific inhibition of each isoform was 
verified by visualizing in the same cell extracts another PKC isoform activation by Tat. 
Fig. 12. Effects of isoform specific PKC inhibition with antisense oligonucleotides on Tat 
induced IL-10 production. 
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was observed with the other isoforms: PKC-,  and  antisense oligonucleotides caused a 
specific down regulation in the level of their corresponding isoforms (figure 12). In 
agreement with the data obtained with chemical inhibitors, an inhibition of Tat induced IL-
10 was observed in the presence of antisense oligonucleotides directed against PKC- 
and. In contrast no significant inhibition was observed with antisense oligonucleotides 
directed against PKC-and - (figure 12) (Bennasser and Bahraoui 2002).  
Overall, it was shown that HIV-1 Tat, activates four PKC isoforms in human monocytes: 
PKC-, PKC- PKC-, and PKC-These data introduce a way to explore the role of PKC 
in signaling pathways in Tat activated monocytes and on search for the partners of PKC- 
and  involved in the production of IL-10, an immunosuppressive cytokine that participates 
in the deregulation of the immune system as early as the asymptomatic stage of HIV-1 
infection. 
Monocytes were treated with sense or antisense oligonucleotides (5, 15 M) specific for 
PKC- PKC- PKC- PKC-fter washing, cells were stimulated with HIV-1 Tat 
protein at 10 nM for 1 hour. Isoform specific PKC inhibition was assessed by western blot 
(bottom). IL-10 production was measured by ELISA 24h later (Sirianni, Vincenzi et al. 1998). 
In each case, specific inhibition of each isoform was verified by visualizing in the same cell 
extracts another PKC isoform activation by Tat. 
2.3.2 Tat activate NF-B pathway 
In this part, we will describe the NF-B signaling pathways implicated in the IL-10 
production induced by Tat protein in the human monocytes, and the mechanism of NF-B 
regulation exploited by this viral protein.  
NF-B is a major transcriptional regulator for the expression of cytokines that are involved 
in the control of the immune and inflammatory response (Baeuerle and Baltimore 1996; 
Baldwin 1996). NF-B is a dimeric transcription factor that consists of REL family members, 
including RelA/p65, c-Rel, RelB, p50 and p52 (Li and Verma 2002). p50 and p52 are derived 
from the larger precursors p105 and p100, respectively, through proteolytic processing by 
the proteasome. All NF-B proteins contain a highly conserved REL-homology domain 
(RHD) that is responsible for DNA binding, dimerization, nuclear translocation and 
interaction with the inhibitory proteins IB within the cytoplasm. The IB proteins, bind to 
NF-B and block its nuclear import and, thereby, its transcriptional activity. The p105 and 
p100 precursors also contain the IB-like repeats that must be degraded to generate the 
mature p50 and p52 subunits, respectively. In contrast to the other NF-B family members, 
p50 lacks a transactivation domain and therefore, usually forms heterodimers with p65 to 
bind to NF-B sites in the nucleus. Homodimers p50:p50 can also be formed but they act as a 
suppressor of inflammatory cytokine gene expression (Ghosh, May et al. 1998). Three 
distinct NF-B activating pathways have emerged (Viatour, Merville et al. 2005) (figure 13).  
Most of our knowledge concerns the “canonical” pathway, which mostly targets ubiquitous 
heterodimers p65:p50 and p50:c-Rel. The critical event in initiating this pathway is 
activation of an IB-phosphorylating protein kinase, IKKKK2, which occurs within the 
“IKK signalosome”, in association with a structurally homologous kinase, IKKIKK1, and 
an adaptor protein, IKKNEMO (Yamaoka, Courtois et al. 1998). IKK-mediated 
phosphorylation of IBand leads to its proteasomal degradation and, hence, activation of 
its associated NF-B dimers that translocate in the nucleus. This pathway is normally 
triggered in response to microbial and viral infections or exposure to pro-inflammatory  
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The classical, alternative and atypical NF-κB-activating pathways as illustrated by the TNF-ǂ-mediated, 
CD40-mediated and DNA-damage-mediated NF-κB activation pathways, respectively. In the classical 
NF-κB-activating pathway, upon binding of TNF-ǂ to TNFR1, SODD is released from the receptor and 
triggers the sequential recruitment of the adaptors TRADD, RIP and TRAF2 to the membrane. Then, 
TRAF2 mediates the recruitment of the IKK complex composed of IKKǂ, IKKǃ and NEMO. Hsp90 and 
Cdc37 are also part of the IKK complex and are required for- IKK activation. Activation of the IKK 
complex leads to the phosphorylation of IκBǂ at specific residues, ubiquitination and its degradation 
via the proteasome pathway. Then, the heterodimer p50–p65 is released and migrates to the nucleus 
where it binds to specific κB sites and activates a variety of NF-κB target genes. The alternative pathway 
is triggered by binding of the CD40 ligand to its receptor, leading to recruitment of TRAF proteins and 
the sequential activation of NIK and IKKǂ, which induces the processing of the inhibitory protein p100. 
p100 proteolysis releases p52 which forms heterodimers with RelB. This pathway is NEMO-
independent and relies on IKKǂ homodimers. The atypical pathway, which is triggered by DNA 
damage relies on sequential p38 and CK2 activations, and involves phosphorylation and degradation of 
subsequent IκBǂ via an IKK-independent pathway. Abbreviations: CK2, casein kinase 2; ELKS, Glu-
Leu-Lys-Ser; Hsp90, heat shock protein 90; IκB, inhibitor of NF-κB; IKK, IκB kinase; NEMO, NF-κB 
essential modulator; NF-κB, nuclear factor-κB; NIK, NF-κB-inducing kinase; RIP, receptor-interacting 
protein; RSK1, ribosomal S6 kinase 1; SODD, silencer of death domains; TNF-ǂ, tumour necrosis factor 
ǂ; TNFR1, TNF receptor 1; TRADD, TNF-receptor-associated death domain protein; TRAF, TNF-
receptor-associated factor; Ub, ubiquitin. 
Fig. 13. Three pathways of NF-B modified by Viatour & al. 2005. 
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cytokines such as tumour necrosis factor TNF By contrast, the “alternative” pathway, 
occurs independently of IKK or NEMO, but is dependent on NF-B -inducing kinase and 
IKK Activation of this pathway leads to a limited proteasomal processing of the NF-B  
precursor protein, allowing the resulting p52 fragment to translocate to the nucleus in 
association with some NF-B proteins (mainly RelB) (Xiao, Harhaj et al. 2001). This pathway is 
triggered by cytokines such as lymphotoxin B (Dejardin, Droin et al. 2002), or CD40 ligand 
(Coope, Atkinson et al. 2002), and by viruses such as the Epstein-Barr virus (Eliopoulos, 
Caamano et al. 2003). The third signaling pathway is classified as “atypical” because it is 
independent of IKK proteins but it still requires the proteasome and is triggered by DNA 
damage such as UV oxidative stress (Imbert, Rupec et al. 1996; Tergaonkar, Bottero et al. 2003). 
However, recent data suggest another role for IKK in NF-B dependent gene expression in 
response to cytokine treatment (Anest, Hanson et al. 2003; Yamamoto, Verma et al. 2003). 
Independently of its previously described cytoplasmic role, IKK functions in the nucleus 
by activating the expression of NF-B-responsive genes after TNF- stimulation. IKK 
recruited to NF-B-responsive promoters, interacts with the histone acetyltransferase 
CBP/p300 (CREB-binding protein). Then it mediates phosphorylation and subsequent 
acetylation of specific residues of histone H3 leading to the NF-B binding sites accessibility.  
In inactivated cells, NF-B is sequestreted in the cytoplasm by the inhibitory protein IB, 
which masks its nuclear localization sequence. In order to be active, NF-B. The 
involvement of NF-B was first tested by the capacity of Tat to activate the nuclear 
translocation of this factor by using the mobility shift technic assay. These experiments were 
performed with an oligonucleotide containing an NF-B site and showed the formation of a 
complex with nuclear extracts of monocytes stimulated with Tat (figure 14). The observed 
interaction between NF-B and the probe seems to be specific, since no complex was 
observed when the protein extract was incubated in the same conditions with the mutated 
NF-B site (Badou and Bennasser 2000).  
In agreement with the inability of this mutant to stimulate the production of IL-10, no 
complex was detected in these conditions. These results showed that Tat induces NF-B 
activation specifically in monocytes. Then the region of Tat involved in NF-B activation 
was investigated by stimulating monocytes with different GST-Tat deleted mutants. EMSA 
analysis showed that only, the C-terminally deleted mutants GST-Tat 1-72 and GST-Tat 1-45 
activate NF-B as the wild type GST-Tat 1-101. In contrast, no activation was observed with 
GST-Tat 30-72 or GST alone (figure 14). These results showed that NF-B activation 
correlates with the ability of Tat and Tat mutant to mediate IL-10 production. In addition the 
role of NF-B activation in the production of IL-10 was evaluated. Monocytes were treated 
with non toxic doses of TLCK (an inhibitor of NF-B pathways), and then stimulated with 
Tat at 10 nM. Then, NF-B activation and IL-10 production were analyzed by EMSA and 
ELISA respectively. In this conditions no NF-B activation nor IL-10 production were 
obtained. Thus, Tat activates transcriptional factor NF-B, one of the substrates of PKC, 
thereby causing induction of IL-10 gene.  
Three distinct NF-B activating pathways have emerged. Interestingly by using the same 
approache we showed that Tat protein is also able to stimulate the nuclear translocation of 
p52 in addition of p65 (figure 15). This results suggest that Tat protein activates both 
classical and alternative NF-B pathways, while TNF- activates only the classical pathway. 
The critical event in initiating this pathway is activation of an IB-phosphorylating protein 
kinase, IKKIKK2, which occurs within the “IKK signalosome”, in association with a 
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structurally homologous kinase, IKKIKK1, and an adaptor protein, IKKNEMO (Yamaoka, 
Courtois et al. 1998). IKK-mediated phosphorylation of Ileads to its proteasomal 
degradation and, hence, activation of its associated NF-B dimers that translocate in the 
nucleus. This pathway is normally triggered in response to microbial and viral infections or 
exposure to pro-inflammatory cytokines such as tumour necrosis factor TNF-. By contrast, 
the “alternative” pathway, occurs independently of IKK or NEMO, but is dependent on NF-
B inducing kinase and IKK Activation of this pathway leads to a limited proteasomal 
processing of the NF-B 2/p100 precursor protein, allowing the resulting p52 fragment to 
translocate to the nucleus in association with some NF-B proteins (mainly RelB).  
 
 
Nuclear protein extracts of human monocytes treated with wild type GST-Tat 1-101 or Tat deleted 
mutants or negatif control GST at 10 nM for 16 h were incubated with a 32P-labeled NF-B probe 
sequence containing the wild type NF-B site. To verify that NF-B activation was specifically 
mediated by Tat, monocytes were treated with chemically mutated Tat (oxidized Tat), and nuclear 
extracts were analyzed by EMSA. 
Fig. 14. Activation of NF-B by HIV-1 Tat 1-45 in human monocytes. 
The analysis of signaling pathways allowed to demonstarte the crucial role of NF-B 
transctivation factor as showed by the capacity of Tat to activate the nuclear translocation of 
the transcription factor NF-B which is shown to be required for the IL-10 production 
(Badou and Bennasser 2000). At the light of the known mechanisms of NF-B activation 
pathways, the molecular mechanisms recruited by Tat to activate NF-B was further 
investigated. To this end, and in order to use transfection approach, we have developed and 
validated the U937 promonocytic cells as model, in addition to primary human monocytes. 
Treated in the same conditions as primary human monocytes, U937 monocytic cells 
produced IL-10 (Leghmari and Bennasser 2008; Contreras 2008). U937 promonocytic cells 
previously cotransfected with a NF-B reporter plasmid, pNF-BLuc, expressing the 
luciferase gene under the control of four NF-B sites and the pCMV-Gal, expressing the -
galactosidase gene under the control of the CMV promoter were treated by different 
concentrations of Tat.The obtained results showed that Tat protein is able to activate NF-B 
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in a dose dependent manner. In agreement with the data obtained in primary human 
monocytic cells, only, the totally Tat protein or its N-terminal fragment Tat 1-45 are able to 
activate NF-B. In contrast no activation was observed with Tat 30-72 or with GST alone 
(Figure 13, 14). 
 
 
Tat induces recruitment of p65 and p52 to the IL-10 promoter. (A) Primary monocytes (107 cells) were 
stimulated or not with Tat 1-86 (10 nM) or TNF-(20 ng/ml). Nuclear extracts were prepared and 
analyzed by Western blot. Anti-TFIIB was used as a loading control. (B) Monocytes were treated or not 
with 10nM Tat 1-86 for 30 min, and ChIP assays were performed with anti-p65, anti-p52 or without (N) 
antibodies. The proportion of co-immunoprecipitated IL-10 promoter was analyzed by quantitative 
realtime PCR. 
Fig. 15. Tat activates classical and alternative NF-B pathways. 
Using negative transdominant mutants of NIK, IKK and IKK, we showed that their 
expression inhibit strongly NF-B activation induced by Tat. Interestingly when both IKK 
and IKK are inhibited simultaneously by their corresponding negative transdominants, 
NF-B activation was totally inhibited. In summury our data indicate that Tat induced NF-
B activation requires NIK, IKK and IKK kinases.  
To adress the question whether Tat was also able to induce nuclear translocation of IKK, 
nuclear extracts from Tat treated cells was analysed by SDS-PAGE and western blot using 
antibodies specific to IKK. This analysis clearly showed that Tat protein is able to stimulate 
IKK translocation from the cytoplasm to the nucleus. This activation is also obtained with 
wild type Tat protein and its N-terminal fragment but not with Tat 30-72. However, recent 
data suggest another role for IKK in NF-B dependent gene expression in response to 
cytokine treatment. Independently of its previously described cytoplasmic role, IKK 
functions in the nucleus by activating the expression of NF-kB-responsive genes after TNF- 
stimulation. IKK recruited to NF-B-responsive promoters, interacts with the histone 
acetyltransferase CBP/p300 (CREB-binding protein). Then it mediates phosphorylation and 
subsequent acetylation of specific residues of histone H3 leading to the NF-B binding sites 
accessibility.  
In summury, Tat protein secreted by infected cells will be taken up by neighboring cells to 
activate HIV-1 replication in HIV-1 infected latent cells, and also to activate non infected 
cells to produce different chemokines and cytokines including IL-10 a highly 
immunosuppressive cytokine greatly implicated in the dysregulation of the immune system 
in HIV-1 infected patients. The analysis of the signaling pathway activated by Tat 
underlined the crucial role of PKC and NF-B pathways. 
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3. Conclusion 
HIV-1 infection hijacks the cellular machinery and uses cellular signaling pathways to its 
own advantage. Early secreted Tat protein, as gp120 via its interaction with CD4 receptor 
and CCR5 coreceptor, trigger a signaling cascade which activates calcium and protein kinase 
C pathways (Contreras 2008; Sieczkarski S et al. 2003 ). All these signaling pathways 
regulate cell activation by acting on the state of cell differentiation, transcription activation, 
cell survival or cytoskeleton dynamics which are required for viral replication (Lamph et al 
1988; Burnette et al 1993; Llewellyn et al 2006). 
Among the activated pathways, PKC pathway plays a critical role for HIV-1 replication. 
Indeed, PKCs stimulate NF-B ( Meichle et al 1990; Junttila et al. 2003; Taunton et al. 2001) 
via the phosphorylation of IκB. NF-B binds to the HIV promoter and is involved in 
initiation and elongation of transcription. In addition, PKCs activate other transcription 
factors like AP-1 and NF-AT, which have specific binding sites on the HIV-1 promoter. 
Thus, activation of PKCs can reverse HIV-1 latency in infected T cells and in cell lines (Guy 
et al. 1987). Moreover, PKCs have been suggested to phosphorylate a number of viral 
proteins such as p17 Gag (Yang et al. 1999), Nef (Popik et al. 1998; Ghosh et al. 1990; 
Hamamoto et al. 1990) and Rev ( Fantuzzi et al. 2000). The PKC pathway is also critical for 
the step of entry of a number of enveloped viruses like rhabdoviruses, alphaviruses and 
herpesviruses (Yang et al 1999) and for type 2 adenovirus (Owen et al. 1996). Thus, the 
understanding of the signaling pathways implicated in the stimulation of virus replication 
or in the production of immunopathogenic cytokines may suggest possible targeted 
therapeutic approaches to neutralize such key steps. 
Taking into account the role of Tat protein in viral replication and induction of 
immunological and neurological disorders, this Tat protein represents a potential vaccine 
candidate (Caputo, Gavioli et al. 2009). Tat protein appears to be an effective candidate to 
include for an HIV vaccine, since its gene product is produced early during the viral life 
cycle. Targeting the immune responses against Tat which plays an important role in viral 
infectivity and pathogenicity could aid in lowering the viral load through the destruction of 
HIV-1 replicating cells by CTL or antibody dependent cell-cytotoxicity. It is important to 
underline the critical role of HIV-1 Tat in the dysregulation of the immune system by the the 
induction of the higly immunosuprressive cytokine: IL-10 (Badou and Bennasser 2000). 
Interestingly several reports showed that humoral or cellular responses against Tat are 
associated with the control of HIV-1 infection as showed by the low viral load and the 
protection against AIDS progression (Wieland et al 1990; Krone et al. 1988; Reiss 1990; Re 
1996; Rezza et al. 2005; Zagury et al. 1998). In agreement with these observations the group 
of Ensoli showed that vaccination of macaque with native Tat protein allowed protection 
against viral infection and disease development (Cafaro et al. 1999; Maggiorella et al. 2004). 
However, experiments performed by other groups showed no protection, or only a partial 
protection in rhesus macaques immunized with native or denatured Tat protein (Allen et al. 
2002; Silvera et al. 2002; Goldstein et al. 2000; Pauza et al. 2000). This apparent discrepancy 
may be related to the nature of animal used cynomolgus versus rhesus and the nature of the 
virus used for the challenge, SHIV89.6P, SIVmac239 or SHIV33. 
It is interesting to note that a therapeutic phase I clinical trial in human, using recombinant 
Tat protein as vaccine candidate is under investigation by the group of Ensoli. 
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